Abstract
Three uracil derivatives of methyl 3-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)propanoate (I), methyl 3-(5-nitro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)propanoate (II) and ethyl 3-(5-nitro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)propanoate (III) have been prepared through one pot synthesis and examined by X-ray crystallography, FT-IR and NMR spectroscopy. Compound I, C8H10N2O4, is monoclinic with space group P 21/c and cell constants a = 11.4437(12), b = 11.7980(13), c = 6.9496(7) A, β = 103.180(2)°, V = 913.57(17) A3, and Z = 4. Compound II, C8H9N3O6, crystallizes in the monoclinic P 21 space group with cell constants a = 8.0342(14), b = 5.7155(10), c = 11.572(2) A, β = 105.200(3)°, V = 512.79(16) A3, and Z = 2. Compound III, C9H11N3O6, is Orthorhombic with space group P 212121 and cell constants a = 5.7560(16), b = 8.032(2), c = 25.302(7) A, β = 90°, V = 1169.8(6) A3, and Z = 4. The supramolecular architectures of the three compounds involve N–H···O hydrogen bond. The supramolecular architectures of the three compounds involve N–H···O hydrogen bond. Depiction of packing and showing the N–H···O hydrogen bond in methyl 3-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)propanoate Depiction of packing and showing the N–H···O hydrogen bond in methyl 3-(5-nitro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)propanoate Depiction of packing and showing the N–H···O hydrogen bond in ethyl 3-(5-nitro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)propanoate.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.